31 results on '"LAWS, ELIZABETH"'
Search Results
2. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
3. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
4. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
5. Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study
6. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study
7. Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroid (VOYAGE)
8. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
9. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
10. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis
11. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
12. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
13. Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics
14. IN THE PHASE 3 BOREAS TRIAL, DUPILUMAB REDUCED FENO LEVELS OVER TIME IN PATIENTS WITH MODERATE OR SEVERE SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH TYPE 2 INFLAMMATION
15. DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EMPHYSEMA
16. IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL
17. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED BOREAS AND NOTUS RESULTS
18. DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE NOTUS TRIAL
19. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL
20. DUPILUMAB IMPROVES RESPIRATORY SYMPTOMS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: POOLED RESULTS FROM BOREAS AND NOTUS
21. EFFICACY AND SAFETY OF DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION
22. ASSESSMENT OF THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN CHILDREN WITH ASTHMA (LIBERTY ASTHMA EXCURSION STUDY)
23. EFFICACY OF DUPILUMAB IN CHILDREN WITH UNCONTROLLED TYPE 2 ASTHMA RECEIVING HIGH/MEDIUM DOSES OF INHALED CORTICOSTEROIDS AT BASELINE: THE LIBERTY ASTHMA VOYAGE STUDY
24. Sa1275 IMPROVEMENTS IN HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS ARE MAINTAINED, OR CONTINUE TO IMPROVE, WITH LONG-TERM DUPILUMAB TREATMENT, REGARDLESS OF PRIOR ESOPHAGEAL DILATION
25. Sa1255 DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN CHILDREN AGED 1 TO
26. 913f DUPILUMAB IS EFFICACIOUS IN EOSINOPHILIC ESOPHAGITIS REGARDLESS OF PRIOR USE OR PRIOR INADEQUATE RESPONSE, INTOLERANCE, OR CONTRAINDICATION TO SWALLOWED TOPICAL CORTICOSTEROIDS: RESULTS FROM PART C OF THE LIBERTY-EOETREET STUDY
27. 605 DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIAL
28. 467 DUPILUMAB IMPROVES HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS, REGARDLESS OF PRIOR HISTORY OF ESOPHAGEAL DILATION
29. Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)
30. Consistent Efficacy Of Dupilumab In Children (6–11 years) With Type 2 Asthma Regardless Of Baseline Demographics And Disease Characteristics
31. Long-Term Dupilumab Treatment Effect On Safety And Clinical Efficacy In Children With Type 2 Asthma: LIBERTY ASTHMA EXCURSION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.